Literature DB >> 20158601

von Willebrand factor activation, granzyme-B and thrombocytopenia in meningococcal disease.

M J Hollestelle1, T Sprong, N Bovenschen, Q de Mast, A J van der Ven, L A B Joosten, C Neeleman, A Hyseni, P J Lenting, P G de Groot, M van Deuren.   

Abstract

SUMMARY
BACKGROUND: During invasive meningococcal disease, severe thrombocytopenia is strongly associated with a poor outcome.
OBJECTIVES: In order to elucidate the pathophysiological mechanism behind the development of thrombocytopenia, we studied the role of von Willebrand factor (VWF) in meningococcal disease. PATIENTS/
METHODS: Thirty-two children with severe meningococcal disease admitted to our university hospital were included in this study. VWF and related parameters were measured and results were correlated with the development of shock and thrombocytopenia.
RESULTS: At admission, all patients had increased levels of (active) VWF and VWF propeptide. The highest VWF propeptide levels were observed in patients with shock, indicating acute endothelial activation. Although VWF propeptide levels in patients with shock, with or without thrombocytopenia, were similar, increased active VWF was significantly lower in patients with thrombocytopenia as compared with patients without thrombocytopenia. ADAMTS13 was moderately decreased. However, the VWF multimeric pattern was minimally increased. We assume that these findings are explained by VWF consumption and perhaps by granzyme B (GrB). In vitro experiments showed that GrB is able to cleave VWF multimers in plasma, whereas GrB was high in patients with shock, who developed thrombocytopenia.
CONCLUSIONS: Our results demonstrate that consumption of VWF, derived from endothelial cells, could be a key feature of meningococcal disease and primary to the development of thrombocytopenia during shock.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20158601     DOI: 10.1111/j.1538-7836.2010.03811.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

Review 1.  Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure.

Authors:  Bradley S Podd; Dennis W Simon; Santiago Lopez; Andrew Nowalk; Rajesh Aneja; Joseph A Carcillo
Journal:  Pediatr Clin North Am       Date:  2017-08-18       Impact factor: 3.278

2.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

3.  Increased active von Willebrand factor during disease development in the aging diabetic patient population.

Authors:  Shuang Feng Chen; Zuo Li Xia; Ji Ju Han; Yi Ting Wang; Ji Yue Wang; Shao Dong Pan; Ya Ping Wu; Bin Zhang; Guang Yao Li; Jing Wei Du; Hen Qiang Gao; Philip G de Groot; Bas de Laat; Martine J Hollestelle
Journal:  Age (Dordr)       Date:  2011-11-27

4.  Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.

Authors:  Martine J Hollestelle; Ka Wai Lai; Marcel van Deuren; Peter J Lenting; Philip G de Groot; Tom Sprong; Niels Bovenschen
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

5.  Prognostic factors among critically ill patients with community-acquired acute bacterial meningitis and acute kidney injury.

Authors:  Sérgio Luiz Arruda Parente Filho; Livia Maria Barbosa Lima; Gilberto Loiola de Alencar Dantas; Débora de Almeida Silva; Victor de Matos Rolim; Antônio Mendes Ponte de Oliveira Filho; Iamê Tavares Vale E Melo; Geraldo Bezerra da Silva Junior; Elizabeth De Francesco Daher
Journal:  Rev Bras Ter Intensiva       Date:  2018 Apr-Jun

6.  Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13.

Authors:  Kis Djamiatun; Andre J A M van der Ven; Philip G de Groot; Sultana M H Faradz; D Hapsari; Wil M V Dolmans; Silvie Sebastian; Rob Fijnheer; Quirijn de Mast
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.